Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 17, 2025
Trial Information
Current as of May 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how fatigue, a common and often underestimated symptom, is related to the side effects experienced by patients receiving CAR-T cell therapy for non-Hodgkin's lymphoma during the first month after treatment. CAR-T cell therapy is a type of immunotherapy that has changed the way some lymphomas are treated, but it can come with various side effects, including fatigue. The researchers want to better understand how these side effects impact patients' lives, particularly their energy levels and overall well-being.
To be eligible for this study, participants must be adults over 18 years old who are hospitalized for CAR-T cell treatment and can read and understand French. Patients under legal protection or those who do not want to participate in research will not be included. Participants can expect to share their experiences regarding fatigue and side effects during this important first month after treatment, helping to improve care for future patients. This study aims to shed light on the connection between treatment side effects and fatigue, ultimately enhancing the support provided to patients undergoing this innovative therapy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (age\> 18year old)
- • Person hospitalised for treatment with CAR-T Cells for non-Hodgkin's lymphoma.
- • Person able to understand and read the French language.
- Exclusion Criteria:
- • Patient under legal protection
- • Opposition to research
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported